Get to know our clinical trials
Phase I/IIa clinical trial of AZD3470 in monotherapy and in combination with anticancer agents in patients with advanced or metastatic MTAP-deficient solid tumors.
THE OBJECTIVE OF THE TRIAL IS TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE RP2D OF AZD3470 AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER AGENTS IN PARTICIPANTS WITH MTAP ADVANCED SOLID TUMORS.
Technical Summary
- Code EudraCT: 2023-506757-38-00
- Protocol number: D9970C00001
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.